40 news items
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
AZN
MRK
MRNA
8 May 24
is approved by the U.S. Food and Drug Administration (FDA) under accelerated approval regulations based on the objective response rate (ORR
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
MRK
8 May 24
and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
ABBV
ATNM
AZN
8 May 24
, primed for M&A interest."
Market Response and Growth Prospects
CytomX Therapeutics Announces Clinical Collaboration With Merck To Evaluate CX-801 In Combination With KEYTRUDA
CTMX
MRK
7 May 24
cancer types. IFNα2b provides a potentially superior approach to activating anti-tumor immune responses compared to other cytokines. CX-801
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
. Ligand is not responsible for, and has no role in, the development of such products or programs.
Ligand
sarfpnjry8si49dn3n9zrkwikw1dzw3hcy
IBRX
MRK
3 May 24
for patients with non-muscle invasive bladder cancer since 1977.
BCG is a benign bacterium that induces an immune response in the bladder
eynpj4zpyvsj p32xfw4xs99toxzq8
MRK
1 May 24
is approved by the U.S. Food and Drug Administration (FDA) under accelerated approval regulations based on the objective response rate (ORR
mrk8mzddkmggih5eab1eflzuwx98rktwgb8nc2
MRK
29 Apr 24
:
V116 elicited immune responses that were noninferior compared to PPSV23 for the 12 serotypes
lg9ryuoszef2uxmaecwgn8xm5gf63vwz4i1bxi04fsdgwpml29pq0v
MRK
25 Apr 24
the serotypes responsible for approximately 83% of invasive pneumococcal disease in adults 65 and older. Merck also announced plans to initiate clinical
1916386g2
IMMP
MRK
24 Apr 24
HNSCC) with negative PD-L1 expression.
The investigational immuno-oncology combination demonstrates an overall response rate (ORR) of 26.9
9bq69tozhfhapf1la63cb3rbn1mminpgphvv4wwbv4c264jy707i54qu7p8c
MRK
19 Apr 24
survival (OS), progression-free survival (PFS) and objective response rate (ORR) compared to placebo in combination with chemotherapy in the intention
6m7fcyc4
MRK
18 Apr 24
their response to recent developments related to Merck & Co. This information provides a snapshot of how analysts perceive the current state
6tng6j1w9kuexigrkktn4hbf3t1vhcdderrzg2ag
ADMA
ANIP
MRK
11 Apr 24
from the study showed that treatment with the combination not only achieved positive clinical responses in HPV- HNSCC patients but even showed
z2ze270s4jmbrlnkszxi rugy583kn
MRK
PCVX
PFE
10 Apr 24
, leading to a stronger immune response.
Vaxcyte also has a 31-valent vaccine. Regarding Merck’s V116, Vaxcyte predicts its
ik4hnlvk7lw8a4r29vmg85f9gfavq3bx5zzoickdc02ojsd9xd mjtygvolk
BMY
JNJ
MRK
10 Apr 24
continues to build its heart business.
Johnson & Johnson is focusing on enhancing its cardiovascular health business in response to its
qotafsst9lijx42pdzjy 702bx
MRK
MRNA
9 Apr 24
patients in patients with a type of head and neck cancer, the vaccine showed a positive response.
mRNA-4157 + pembrolizumab was associated
deo57qwpzpvvb9is5zlo5v3ms4xn8kjoc00k4ikgsjdzi85ot8nb
MRK
4 Apr 24
, and key secondary endpoints include objective response rate and duration of response.
kwvzr9xywqj4d4onqoxuugh4ssb02m8hf
MRK
4 Apr 24
survival and overall survival, and key secondary endpoints include objective response rate and duration of response
frwla8z9gwsq1icd9r4etu0d5pios7s
MRK
1 Apr 24
, it signifies their response to recent developments related to Merck & Co. This offers insight into analysts' perspectives on the current state
mdr r13enh
MRK
28 Mar 24
secondary endpoints include pathologic complete response (pCR) and major pathological response (mPR). The study enrolled 797 patients who were randomly